Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard C. Szirth is active.

Publication


Featured researches published by Bernard C. Szirth.


British Journal of Cancer | 1988

Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model

Les White; Charles J. Gomer; Daniel R. Doiron; Bernard C. Szirth

Haematoporphyrin derivative (HPD) photodynamic therapy (PDT) may have clinical application in the management of patients with retinoblastoma. Heterotransplantation of retinoblastoma cells into the anterior chamber of the nude mouse eye and the subsequent growth of small tumour masses has provided a model for evaluation of various therapeutic modalities. Ninety-four evaluable xenograft tumours in 54 nude mice were randomized to receive one of the following treatments: cyclophosphamide (CPM) alone, HPD-PDT alone, CPM followed by HPD-PDT, HPD-PDT followed by CPM, or saline control. Responses were demonstrated after CPM treatment in all three relevant groups. However, HPD-PDT was found to be ineffective either alone or as a contributor in the double modality treatment groups. The small tumour masses treated can be demonstrated histologically to be avascular. It is proposed that although the same retinoblastoma cells in different circumstances are responsive to HPD-PDT, no clinical response is demonstrable utilizing this model, due to the absence of tumor vascularity.


Current Eye Research | 1984

Hematoporphyrin derivative photoradiation induced damage to normal and tumor tissue of the pigmented rabbit eye

Charles J. Gomer; Daniel R. Doiron; Les White; James V. Jester; Scott Dunn; Bernard C. Szirth; Nicholas J. Razum; A. Linn Murphree

Cytotoxicity induced by hematoporphyrin derivative (HpD) photoradiation in both normal and experimental tumor tissue of pigmented rabbit eyes has been examined. In addition, documentation of HpD induced fluorescence in ocular structures has also been obtained. Acute normal ocular tissue toxicity studies demonstrated that HpD (1-10 mg HpD/kg) followed 48 hours later by a transpupil irradiation of red light (635 nm, 36-90 J/cm2) resulted in demarcated areas of retinal damage. Long term (chronic) toxicity studies have shown that the initial damage to the retina was permanent but that no damage to the cornea, lens or vitreous could be observed during a 16 month follow-up. Visual and histological documentation have been obtained, following HpD photoradiation therapy (PRT), in rabbit eyes having heterotransplanted single nodule amelanotic melanomas. A toxic effect characterized by tumor blanching, edema and hemorrhage was observed within 24 hours of treatment. Histological examination obtained 24 hours following HpD PRT illustrated massive tumor tissue necrosis and vascular disruption. HpD PRT at clinically relevant doses was also shown to be effective in selectively curing the highly malignant amelanotic iris melanoma. It is concluded that HpD PRT may prove to be an effective modality for treating certain ocular tumors.


Cancer Chemotherapy and Pharmacology | 1989

Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice

Les White; Bernard C. Szirth; William F. Benedict

SummaryThe role of chemotherapy in the treatment of retinoblastoma (RB) is unsatisfactory and clinical research is severely limited. A xenograft model for testing chemotherapeutic and other atents has been developed by the heterotransplantation of human RB cells into the anterior chamber of the nude mouse eye. A grading system for visually monitored tumor growth was designed to allow serial observations and documentation of the response to therapy in the model. This method of monitoring compared favorably with histopathologic, photographic, or other criteria in the reproducible, sequential evaluation of tumor status. Six chemotherapeutic agents [vincristine (VCR), doxorubicin (DOX), actinomycin D (ACT-D), dimethyltriazeno-imidazole carboxamide (DTIC), cyclosphosphamide (CMP), and diaziquone (AZQ)] were then tested in the model against a patient-derived xenograft line. Results were expressed as the delay in tumor progression judged by serial grading. CPM produced a consistent response in all treated tumors, as did DTIC to a lesser, more variable extent. In 3 of 10 tumors treated with CPM and in 1 of 18 treated with DTIC, complete responses were maintained for at least 20 weeks. VCR, DOX, and ACT-D were ineffective, producing patterns of tumor progression no different from those in the control group. AZQ was most effective, producing responses far exceeding those of conventional agents. The model allows quantitative documentation of the response to therapy in heterotransplanted human RB. Further testing of new agents and combinations is warranted. AZQ may be active against RB.


Archive | 1984

Preclinical Examination of Ocular Photoradiation Therapy

Charles J. Gomer; A. Linn Murphree; Daniel R. Doiron; Bernard C. Szirth; Nicholas J. Razum

Hematoporphyrin derivative photoradiation therapy is an effective therapeutic modality for several types of solid tumors 1,2. One area of recent clinical interest is the exploitation of HpD PRT for the treatment of ocular malignancies 3,4. New therapies which can provide effective tumor destruction and minimal normal ocular tissue damage are needed since the current modalities used for treating eye tumors (external beam radiation, radioisotope plaques, photocoagulation and cryotherapy) are not totally satisfactory 5,6. HpD PRT may provide a modality which can be utilized for the treatment of both retinoblastoma and uveal melanoma. In addition, this procedure may be useful as both a primary modality in selective instances as well as a secondary modality following recurrence.


Advances in Experimental Medicine and Biology | 1983

Preclinical Evaluation of Hematoporphyrin Derivative for the Treatment of Intraocular Tumors: A Preliminary Report

Charles J. Gomer; Bernard C. Szirth; D. R. Doiron; J. V. Jester; Robert W Lingua; C. Mark; William F. Benedict; Al Murphree

Treatment modalities such as external beam radiation therapy, cobalt plaques, photocoagulation or cryotherapy for preservation of useful vision in patients with ocular tumors offer only limited success. In many cases enucleation is necessary in order to prevent tumor spread (1). The accessibility of intraocular tumors to visible light and the excellent optical properties of the eye suggest that hemato-porphyrin derivative photoradiation therapy (HPD PRT) may prove to be an important advancement in the successful management of intraocular and periocular malignancies. Due to the extreme sensitivity of the eye to light and the possible loss of vision resulting from non-repairable damage to normal ocular structures, we are performing preclinical studies designed to evaluate the efficacy of HPD PRT as a primary clinical modality for treating ocular tumors.


Advances in Photochemotherapy | 1989

Cellular And Preclinical Examination Of Photodynamic Therapy

Charles J. Gomer; Angela Ferrario; Natalie Rucker; Sam Wong; Elisa N. Morinelli; Grace Ying-Shi Liu; Bernard C. Szirth

In-vitro studies have been performed to compare the mode of action of porphyrin induced photodynamic therapy and hyperthermia. Parent and temperature resistant clones of Chinese hamster and mouse fibrosarcoma cells were treated with either PDT or hyperthermia. Quantitative survival curves obtained from these experiments indicate that temperature resistant cells are not cross resistant to PDT even though both treatments induce the synthesis of stress proteins. In-vivo studies were performed to evaluate the photosensitizing efficiency to mono-l-aspartyl chlorin e 6 (NPe6). Tumor response and normal skin response were determined using a murine tumor system. The studies indicate that NPe6 is an extremely effective tumor photosensitizer with rapid in-vivo clearance properties which may eliminate the side effects of prolonged and systemic skin photosensitivity.


Lasers in Surgery and Medicine | 1988

Molecular, cellular, and tissue responses following photodynamic therapy

Charles J. Gomer; Angela Ferrario; Naganobu Hayashi; Natalie Rucker; Bernard C. Szirth; A. Linn Murphree


Cancer Research | 1985

Photodynamic Therapy of Intraocular Tumors Examination of Hematoporphyrin Derivative Distribution and Long-Term Damage in Rabbit Ocular Tissue

Charles J. Gomer; James V. Jester; Razum Nj; Bernard C. Szirth; Murphree Al


Archive | 1994

Eye imaging system

Bernard C. Szirth; Alan Linn Murphree; Steven Eugene Lusty; James A. Burris


Cancer Research | 1983

Hematoporphyrin Derivative Photoradiation Therapy for the Treatment of Intraocular Tumors: Examination of Acute Normal Ocular Tissue Toxicity

Charles J. Gomer; Daniel R. Doiron; James V. Jester; Bernard C. Szirth; A. Linn Murphree

Collaboration


Dive into the Bernard C. Szirth's collaboration.

Top Co-Authors

Avatar

Charles J. Gomer

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

A. Linn Murphree

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Daniel R. Doiron

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Les White

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

James V. Jester

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Angela Ferrario

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar

Natalie Rucker

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Nicholas J. Razum

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Robert W Lingua

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

William F. Benedict

University of Southern California

View shared research outputs
Researchain Logo
Decentralizing Knowledge